Ensil Canada Ltd. Markham, Ontario, Canada, Today Announced the Validation of a 5-Minute, Non-Invasive HIV Test at its Laboratories in Ontario, Canada
After several years of scientific and biomedical laboratory experiments, Ensil succeeds in developing a nanotechnology-based sensor to detect gp 21 and gp 27 HIV virus through urine.

MARKHAM, ON, January 03, 2012 /24-7PressRelease/ -- After several years of scientific and biomedical laboratory experiments, Ensil succeeds in developing a nanotechnology-based sensor to detect gp 21 and gp 27 HIV virus through urine.

"After several years of scientific and biomedical laboratory experiments to develop nanotechnology-based sensors and detectors, we are extremely proud to make this announcement," said Farsad Kiani, Presiden and CEO of Ensil Group of Companies.

Mr. Kiani continued, "When the Ensil Canada Ltd. HIV diagnostic device is commercialized and put on the market, high-risk groups may get tested at more convenient locations as a do-it-yourself, real-time, cost-effective way to test and receive their own test results in strictest confidence."

Ensil Canada Ltd. Chief Scientist and the Lead Project CSO added after the successful experiments with the antibody to HIV gp41, Ensil will try to validate the same results with its proprietary detection technology to detect gp120 so a wide range of HIV strain could be detected.

Press Release Contact Information:

Louis Koikas
Ensil Canada Ltd.
Senior VP
205 Torbay Road
Markham, Ontario
Canada L3R3W4
Voice: 905-479-6979
Fax: 905-479-3185
Website: Visit Our Website